JP Morgan Chase’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-714,679
| Closed | -$9.36M | – | 7519 |
|
|
2025
Q4 | $9.36M | Sell |
714,679
-965,928
| -57% | -$11.5M | ﹤0.01% | 2745 |
|
|
2025
Q3 | $12.2M | Sell |
1,680,607
-15,464
| -0.9% | -$105K | ﹤0.01% | 2541 |
|
|
2025
Q2 | $9.09M | Buy |
1,696,071
+1,660,039
| +4,607% | +$8.05M | ﹤0.01% | 2645 |
|
|
2025
Q1 | $192K | Sell |
36,032
-18,632
| -34% | -$130K | ﹤0.01% | 5260 |
|
|
2024
Q4 | $489K | Buy |
54,664
+15,520
| +40% | +$165K | ﹤0.01% | 5054 |
|
|
2024
Q3 | $431K | Buy |
39,144
+19,735
| +102% | +$219K | ﹤0.01% | 4991 |
|
|
2024
Q2 | $177K | Sell |
19,409
-69
| -0.4% | -$674 | ﹤0.01% | 5218 |
|
|
2024
Q1 | $274K | Sell |
19,478
-2,404
| -11% | -$29.9K | ﹤0.01% | 5166 |
|
|
2023
Q4 | $168K | Buy |
21,882
+4,545
| +26% | +$25.1K | ﹤0.01% | 5485 |
|
|
2023
Q3 | $129K | Sell |
17,337
-10,256
| -37% | -$87.5K | ﹤0.01% | 5330 |
|
|
2023
Q2 | $230K | Buy |
+27,593
| New | +$318K | ﹤0.01% | 4996 |
|
|
2022
Q4 | – | Sell |
-299
| Closed | -$3K | – | 6532 |
|
|
2022
Q3 | $3K | Buy |
+299
| New | +$2K | ﹤0.01% | 6174 |
|
|
2021
Q3 | – | Sell |
-3,635
| Closed | -$46K | – | 6469 |
|
|
2021
Q2 | $46K | Buy |
3,635
+2,281
| +168% | +$29.6K | ﹤0.01% | 5755 |
|
|
2021
Q1 | $23K | Sell |
1,354
-139
| -9% | -$2.51K | ﹤0.01% | 5680 |
|
|
2020
Q4 | $19K | Sell |
1,493
-764
| -34% | -$13.6K | ﹤0.01% | 5306 |
|
|
2020
Q3 | $83K | Buy |
2,257
+1,246
| +123% | +$49.4K | ﹤0.01% | 4777 |
|
|
2020
Q2 | $39K | Sell |
1,011
-1,066
| -51% | -$38K | ﹤0.01% | 4901 |
|
|
2020
Q1 | $52K | Sell |
2,077
-6,671
| -76% | -$207K | ﹤0.01% | 4711 |
|
|
2019
Q4 | $310K | Buy |
8,748
+3,396
| +63% | +$107K | ﹤0.01% | 4489 |
|
|
2019
Q3 | $173K | Sell |
5,352
-1,882
| -26% | -$74.4K | ﹤0.01% | 4695 |
|
|
2019
Q2 | $339K | Buy |
7,234
+5,517
| +321% | +$250K | ﹤0.01% | 4415 |
|
|
2019
Q1 | $82K | Buy |
+1,717
| New | +$58.2K | ﹤0.01% | 4955 |
|
|
2018
Q2 | – | Sell |
-24
| Closed | -$3K | – | 5539 |
|
|
2018
Q1 | $3K | Buy |
+24
| New | +$2.4K | ﹤0.01% | 5263 |
|
JP Morgan Chase's ATXS Position: Q1 2026 in Review
JP Morgan Chase sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 714,679 shares — an estimated $9.36M sold.
JP Morgan Chase first reported a position in ATXS in Q1 2018 and held it in 23 quarters. The position peaked at $12.2M in Q3 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- JP Morgan Chase reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 714,679 Astria Therapeutics shares in Q1 2026, an estimated $9.36M.
- JP Morgan Chase first reported a position in Astria Therapeutics in Q1 2018 and held it in 23 quarters.
- JP Morgan Chase's Astria Therapeutics position peaked at $12.2M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.